drugset
Drugs / Personalized mRNA Tumor Vaccine
last change Dec 2025 re-read 3 minutes ago

Personalized mRNA Tumor Vaccine

Messenger RNA (mRNA)

Developed for
colorectal adenocarcinoma · esophageal cancer · esophageal squamous cell carcinoma · gastric adenocarcinoma · non-small cell lung carcinoma · pancreatic adenocarcinoma
Investigated by
Stemirna Therapeutics · Changhai Hospital · The First Affiliated Hospital of Zhengzhou University

Trials 2

today NCT03908671 · not/applicable NCT03468244 · not/applicable
201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT03908671 Oct 2019 → Oct 2024 esophageal cancer, non-small cell lung carcinoma Stemirna Therapeutics Unknown No outcome recorded
— NCT03468244 May 2018 → Dec 2019 colorectal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma Changhai Hospital Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Personalized mRNA Tumor Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03908671 ↗
1

NCT03468244 ↗
Modality Messenger RNA (mRNA) “personalized mRNA (messenger RNA) vaccine treatment” PMID 39267685 ↗ Aug 2024
Route Subcutaneous “subcutaneous injection with personalized mRNA tumor vaccine at least four times” NCT03468244 ↗